Source comparison
GHRP-2 vs Ipamorelin: The Selectivity Spectrum
Both compounds in the GHRP-2 vs Ipamorelin comparison bind the same GHS-R1a ghrelin receptor. The difference is in binding geometry and downstream pathway activation — what researchers call biased agonism. Ipamorelin’s specific binding configuration favors the
This comparison does not assign a generated winner or score.
- Both compounds in the GHRP-2 vs Ipamorelin comparison bind the same GHS-R1a ghrelin receptor. The difference is in binding geometry and downstream pathway activation — what researchers call biased agonism. Ipamorelin’s specific binding configuration favors the somatotroph GH-release signaling pathway while producing negligible activation of corticotroph (cortisol) and lactotroph (prolactin) pathways. GHRP-2’s broader activation engages all three cell populations.
- Published research consistently shows this selectivity difference across dose ranges: Ipamorelin produces no statistically significant cortisol or prolactin elevation even at very high concentrations. GHRP-2 produces measurable cortisol elevation at standard research doses. In the GHRP-2 vs Ipamorelin comparison, this selectivity gap is the defining pharmacological distinction.